Glivec® International Patient Assistance Program (GIPAP)
The Glivec® International Patient Assistance Program (GIPAP) run by THE MAX Foundation in cooperation with Novartis is one of the most comprehensive and far-reaching cancer access programs ever developed on a global scale. Since its implementation in early 2002, GIPAP has provided Glivec® to more than 49,000 patients in 80 developing countries with minimal reimbursement capabilities who would not otherwise have access to the drug to treat their life-threatening diseases.